Human Umbilical Cord Blood Plasma-Derived Exosomal miR-410-3p Alleviates Liver Injury by Regulating the
Lin Zhang1, Yushuang Ren1, Dongsheng Su1
1Department of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital, Sichuan University Chengdu China.
Insights
Umbilical cord blood exosomes (CBP-Exos) show potent liver repair capabilities. These exosomes, particularly miR-410-3p, protect against liver injury by inhibiting hepatocyte apoptosis and oxidative stress.
Area of Science:
- Regenerative Medicine
- Molecular Biology
- Hepatology
Background:
- Severe liver injury presents significant mortality and limited treatment options.
- Young blood has shown regenerative potential, but the efficacy of umbilical cord blood for tissue repair is not well understood.
- Exosomes are key mediators of intercellular communication and hold therapeutic promise.
Purpose of the Study:
- To investigate the therapeutic potential of exosomes derived from umbilical cord blood plasma (CBP-Exos) in liver injury models.
- To elucidate the underlying molecular mechanisms of CBP-Exos in promoting liver regeneration and repair.
- To compare the efficacy of CBP-Exos with exosomes from young peripheral blood plasma.
Main Methods:
- Establishment of acute and chronic liver injury mouse models.
- Administration of CBP-Exos and assessment of liver tissue damage, including necrosis, lipid peroxidation, and apoptosis.
- Mechanistic studies involving microRNA (miR-410-3p) analysis, gene targeting (Bim), and evaluation of apoptotic signaling pathways (Bcl2-CytoC axis).
- Overexpression of miR-410-3p to validate its role in liver protection.
Main Results:
- CBP-Exos significantly reduced liver necrosis, lipid peroxidation, and apoptosis in acute liver injury (ALI) mice.
- CBP-Exos demonstrated superior therapeutic effects compared to exosomes from young peripheral blood plasma.
- miR-410-3p within CBP-Exos was identified as a key therapeutic component, targeting Bim to inhibit apoptosis via the Bcl2-CytoC pathway.
- Overexpression of miR-410-3p improved liver function in ALI mice.
Conclusions:
- CBP-Exos possess significant therapeutic potential for both acute and chronic liver injury.
- The miR-410-3p/Bcl2/CytoC axis is a critical mechanism by which CBP-Exos exert protective effects against liver damage.
- These findings support the clinical application of CBP-Exos and miR-410-3p for treating liver diseases.
Abstract:
Severe liver injury is a life-threatening condition with high mortality and limited therapeutic options. Extensive research on heterochronic parabiosis has highlighted the potent regenerative repair capabilities of young blood in tissue regeneration. However, it remains unclear whether younger blood, specifically umbilical cord blood, can offer similar benefits for tissue repair. In this study, we demonstrate that exosomes derived from umbilical cord blood plasma (CBP-Exos) exhibit significant therapeutic effects in both acute and chronic liver injury models, outperforming exosomes from young peripheral blood plasma. Treatment with CBP-Exos notably reduced liver necrosis, lipid peroxidation, and apoptosis in liver tissues of acute liver injury (ALI) mice. Mechanistically, miR-410-3p, derived from CBP-Exos, directly targets the proapoptotic gene Bim for posttranscriptional degradation. The downregulation of Bim facilitates the activation of mitochondrial-mediated Bcl2-CytoC antiapoptotic signaling, resulting in the restoration of mitochondrial structure and function, thereby inhibiting hepatocyte apoptosis and oxidative stress. Furthermore, overexpression of miR-410-3p significantly improved liver function in ALI mice. These findings identify the therapeutic effects of CBP-Exos are attributed to the miR-410-3p/Bcl2/CytoC axis, laying a foundation for the clinical application of CBP-Exos and miR-410-3p in liver diseases.
More Related Videos
10:42Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
Published on: April 11, 2019
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
